What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

1. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.Journal of the National Cancer Institute · 2020
   Pooled it
2. Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives.Biomedicines · 2025
   Review
3. DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response.Cancer science · 2025
   Review
4. BRCA1/2 methylation and expression dynamics in hereditary breast and ovarian cancer: insights from gene, protein, and TCGA analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
   Article
5. DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications.Cancer medicine · 2025
   Review
6. Current data and future perspectives on DNA methylation in ovarian cancer (Review).International journal of oncology · 2024
   Review
7. ConstitutionalInternational journal of molecular sciences · 2024
   Article
8. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.Annals of medicine · 2023
   Review
9. Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers.Cancers · 2022
   Article
10. Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management.Seminars in cancer biology · 2021
    Review
11. Detection of hypermethylation BRCA1/2 gene promoter in breast tumours among Moroccan women.Molecular biology reports · 2021
    Article
12. Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.Experimental biology and medicine (Maywood, N.J.) · 2021
    Article
13. Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.Obstetrics & gynecology science · 2020
    Article
14. BRCA1 promoter hypermethylation in human placenta: a hidden link with β-hCG expression.Carcinogenesis · 2020
    Article
15. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.Nature communications · 2019
    Article
16. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2019
    Article
17. Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.Gynecologic oncology reports · 2017
    Review
18. Aberrant promoter methylation of cancer-related genes in human breast cancer.Oncology letters · 2016
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

15 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as